Neuromed's extended-release hydromorphone successful in US Phase III trials
This article was originally published in Scrip
Executive Summary
Neuromed Pharmaceuticals' lead investigational product, the extended-release opioid analgesic Exalgo (hydromorphone HCl), has met its primary efficacy endpoint in its pivotal US Phase III clinical trial, the company reports.